Japan, Sept. 28 -- NANTKWEST INC has got intellectual property rights for 'ANTIBODY PRE-LOADED CD16+NK-92 CELLS AS EFFECTIVE THERAPEUTIC PRODUCT FOR TUMOR LYSIS.' Other related details are as follows:
Application Number: JP,2024-155430
Category (FI): A61K35/17,A61K40/42,C12N1/00@F,C12N7/01,C12N1/19,A61K40/15,C12N1/04,C07K14/76,C07K16/28,C12N5/10,C07K14/55,C12N5/0783,A61K31/7068,A61K31/706,A61K31/675,A61K31/513,A61K31/4745,A61K45/00,A61P43/00,121,A61P35/00,A61K39/395@N,A61K39/395@D,A61K40/35
Stage: Grant (IP right granted following substantive examination.)
Filing Date: Sept. 10, 2024
Publication Date: Dec. 10, 2024
The original document can be viewed at: https://www.j-platpat.inpit.go.jp/p0100
Disclaimer: Curated by HT Syndication....